The 38 references in paper Rami Al-Ayyubi N., Evgeny Merkulov V., Andrey Tereschenko S., Dmitry Pevzner V., Natalia Zhukova S., Anatoly Samko N., Ruslan Guchaev V., Р. Аль-Айюби Н., Е. Меркулов В., А. Терещенко С., Д. Певзнер В., Н. Жукова С., А. Самко Н., Р. Гучаев В. (2018) “ЭНДОВАСКУЛЯРНАЯ ПРОФИЛАКТИКА ТРОМБОЭМБОЛИЙ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ // THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION” / spz:neicon:aterotromboz:y:2018:i:2:p:104-114

1
Линчак Р.М., Компаниец О.Г., Недбайкин А.М. и др. Каковы реалии назначения и контроля антитромботической терапии при фибрилляции предсердий в амбулаторной практике? Кардиология. 2015; 55(6): 34-39. [Lynchak R.M., Kompaniets o.G., nedbaykin A.M., et al. What are the realities of prescription and control ofantithrombotic therapy in atrial fibrillation in outpatient practice? Kardiologia. 2015; 55 (6): 34-39]. (in Russ).
(check this in PDF content)
2
Mamchur s.e., Mamchur I.n., Khomenko e.A. et al. Catheter ablation for atrial fibrillation after an unsuccessful surgical ablation and biological prosthetic mitral valve replacement: A pilot study. J. Chin. med. Assoc. 2014; 77(8): 409-415.
(check this in PDF content)
3
Kwong J.s., Lam Y.Y., Yan B.P., Yu C.M. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc. drugs Ther. 2013; 27: 23-35.
(check this in PDF content)
4
Королева Т.В., Яфарова А.А., Щукина В.В., Григорян А.В. Современная антикоагулянтная терапия при фибрилляции предсердий. научная дискуссия: вопросы медицины. 2016; 6(37): 22-26. [Koroleva t.V., Yafarova A.A., shchukina V.V., Grigoryan A.V. Modern anticoagulant therapy for atrial fibrillation. nauchnaya diskussiya: Voprosy mediciny. 2016; 6 (37): 22-26]. (in Russ).
(check this in PDF content)
5
Chugh s.s., Havmoeller R., narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. 2014; 129: 837–847.
(check this in PDF content)
6
Лебедев Д.С., Михайлов Е.Н., Новикова Т.Н. и др. Соглашение экспертов Санкт-Петербургского отделения Всероссийского научного общества аритмологов по периоперационной антикоагулянтной терапии у пациентов с фибрилляцией и/или трепетанием предсердий, направленных на катетерное лечение нарушений ритма сердца или имплантацию антиаритмических устройств. вестник аритмологии. 2016; 86: 72-77. [Lebedev D.s., Mikhailov e.n., novikova t.n ., et al. the consensus of experts of st. Petersburg branch of the All-Russian scientific society of Arrhythmology on perioperative anticoagulant therapy in patients with atrial fibrillation and/or atrial flutter aimed at using catheter treatment of heart rhythm disturbances or implantation of antiarrhythmic devices. Vestnik Aritmologii. 2016; 86: 72-
(check this in PDF content)
7
Кропачева Е.С., Панченко Е.П. Вопросы безопасности терапии больных с фибрилляцией предсердий. атеротромбоз. 2016; 2: 127-139. [Kropacheva e.s., Panchenko e.P. safety issues of therapy in patients with atrial fibrillation. Aterotromboz. 2016; 2: 127-139]. (in Russ).
(check this in PDF content)
8
Denas G., Gennaro n., Ferroni e. et al. effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: Propensity score matched cohort study. Int J Cardiol. 2017; 249: 198-203.
(check this in PDF content)
9
Madden J.L. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. J. Am. med. Assoc. 1949; 140: 769-772.
(check this in PDF content)
10
Blackshear J.L., odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 1996; 61: 755-759.
(check this in PDF content)
11
Самко А.Н., Меркулов Е.В., Миронов В.М. и соавт. Эндоваскулярное закрытие ушка левого предсердия у больных с мерцательной аритмией: обзор современных данных и собственный опыт применения. Кардиология. 2013; 4: 88-92./ samko An, Merkulov eV, Mironov VM, et al. endovascular cloэндоваскулярной изоляции УЛП является возможность их использования у пациентов с противопоказаниями к антикоагулянтам. Несмотря на хорошие непосредственные и среднеотдаленные результаты использования устройств для эндоваскулярной изоляции УЛП, у метода есть ряд ограничений. Основным является отсутствие наблюдений в отдаленном периоде и сравнение с пациентами, принимающими НОАК. Целесообразным представляется проведение дальнейших исследований по уточнению показаний к использованию устройс
(check this in PDF content)
12
Pracon R., Grygoruk R., Dzielinska Z. et al. Percutaneous occlusion of the left atrial appendage with complex anatomy facilitated with 3D-printed model of the heart. EuroIntervention. 2016; 12(7): 9 27.
(check this in PDF content)
13
Di Biase L., Burkhardt J.D., Mohanty P. et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2011; 122: 109-118.
(check this in PDF content)
14
starck C.t., steffel J., emmert M.Y. et al. epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage. Interact. Cardiovasc. Thorac. Surg. 2012; 15: 416-418.
(check this in PDF content)
15
sievert H., Lesh M.D., trepels t. et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002, 105: 1887-1889.
(check this in PDF content)
16
nakai t., Lesh M.D., Gerstenfeld e.P. et al. Percutaneous left atrial appendage occlusion (PLAAto) for preventing cardioembolism: first experience in canine model. Circulation. 2002; 105: 2217-2222.
(check this in PDF content)
17
ostermayer s.H., Reisman M., Kramer P.H. et al. Percutaneous left atrial appendage transcatheter occlusion (PLAAto system) to prevent stroke in highrisk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J. Am. Coll. Cardiol. 2005; 46: 9-14.
(check this in PDF content)
18
Block P.C., Burstein s., Casale P.n. et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAAto (Percutaneous Left Atrial Appendage transcatheter occlusion) study. JACC Cardiovasc. Interv. 2009; 2: 594-600.
(check this in PDF content)
19
Bayard Y.L., omran H., neuzil P. et al. PLAAto (Percutaneous Left Atrial Appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the european PLAAto study. Euro Intervention. 2010; 6: 220-226.
(check this in PDF content)
20
Meier B., Palacios I., Windecker s. et al. transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc. Interv. 2003; 60: 417-422.
(check this in PDF content)
21
el-Gabry M., shehada s., Wendt D., Mourad F. emergent surgical removal of a migrated left atrial appendage occlude. Eur. J. Cardiothorac. Surg. 2018; 54(1): 191-192.
(check this in PDF content)
22
Guerios e.e., schmid M., Gloekler s. et al. Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. Arq. Bras. Cardiol. 2012; 98: 528-536.
(check this in PDF content)
23
Majule D.n., Jing C., Rutahoile W.M., shonyela Fs. the efficacy and safety of the WAtCHMAn Device in LAA occlusion in Patients with non-Valvular Atrial Fibrillation Contraindicated to oral Anticoagulation: A Focused Review. Ann. Thorac. Cardiovasc. Surg. 2018 Jun 29; [epub ahead of print].
(check this in PDF content)
24
sick P.B., schuler G., Hauptmann K.e et al. Initial worldwide experience with the WAtCHMAn left atrial appendage system for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 2007; 49: 1490-1495.
(check this in PDF content)
25
Holmes D.R., Reddy V.Y., turi Z.G. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374: 534-542.
(check this in PDF content)
26
Reddy V.Y., Holmes D., Doshi s.K. et al. safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage system for embolic Protection in Patients with AF (PRoteCt AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123: 417-424.
(check this in PDF content)
27
Reddy V.Y., Doshi s.K., sievert H. et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PRoteCt AF (Watchman Left Atrial Appendage system for embolic Protection in Patients with Atrial Fibrillation) trial. Circulation. 2013; 127: 720-729.
(check this in PDF content)
28
Holmes DR Jr., Kar s., Proce MJ., et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long term warfarin: the PReVAIL trial. J. Am. Coll. Cardiol. 2014; 64: 1-12.
(check this in PDF content)
29
Gianni C., Di Biase L., trivedi C. et al. Clinical implications of leaks following left atrial appendage ligation with the LARIAt device. JACC Cardiovasc. Interv. 2016; 9(10): 1051–1057.
(check this in PDF content)
30
Lee R.J., Bartus K., Yakubov s.J. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: Initial experience in a canine model. Circ. Cardiovasc. Interv. 2010; 3: 224-229.
(check this in PDF content)
31
Bartus K., Han F.t., Bednarek J. et al. Percutaneous left atrial appendage suture ligation using the LARIAt device in patients with atrial fibrillation: initial clinical experience. J. Am. Coll. Cardiol. 2013; 62: 108-118.
(check this in PDF content)
32
Miller M.A., Gangireddy s.R., Doshi s.K. et al. A Multi-Center study on Acute and Long-term safety and efficacy of Percutaneous Left Atrial Appendage Closure using an epicardial suture snaring Device. Heart rhythm. 2014; 11(11): 1853-1859.
(check this in PDF content)
33
Matthew J., Price M., Douglas n. et al. early safety and efficacy of Percutaneous Left Atrial Appendage suture Ligation Results from the U.s. transcatheter LAA Ligation Consortium. J. Am. Coll Cardiol. 2014; 64: 565–572.
(check this in PDF content)
34
Di Biase L., Burkhardt J.D., Gibson D.n., natale A. 2D and 3D tee evaluation of an early reopening of the LARIAt epicardial left atrial appendage closure device. Heart rhythm. 2014; 11: 1087-1088.
(check this in PDF content)
35
Yeow W.L., Matsumoto t., Kar s. successful closure of residual leak following LARIAt procedure in a patient with high risk of stroke and hemorrhage. Catheter Cardiovasc. Interv. 2014; 83(4): 661-663.
(check this in PDF content)
36
Lam Y.Y. A new left atrial appendage occluder (Lifetech LAmbre Device) for stroke prevention in atrial fibrillation. Cardiovasc. revasc. med. 2013; 14: 134 -13 6 .
(check this in PDF content)
37
toumanides s., sideris e.B., Agricola t., Moulopoulos s. transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high-risk patients with atrial fibrillation. J. Am. Coll. Cardiol. 2011; 58: 2236-2240.
(check this in PDF content)
38
Romero J., natale A., engstrom K., Di Biase L. Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices: Pre-clinical and clinical experience. Trends Cardiovasc. med. 2016; 26(2): 182-199.
(check this in PDF content)